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E-mail address: alessandra.vigano@Abstract Objectives. To characterize the efficacy and tolerability of multiple drug
therapy (MDT) among heavily pre-treated HIV-infected children.
Methods. An observational study of seven children treated with 4–7 antiretroviral
agents. MDT regimens were chosen with regard to past antiretroviral exposure and
genotypic resistance data. Five children received MDT once, one child twice and one
child four times. All patients had AIDS and severe CD4C depletion and failedO2 PI-
based HAART regimens.
Results. Virologic response, defined as aRlog10 decrease in plasma HIV-1 RNA at
week 24, was achieved in 7/11 MDT. Successful MDT kept a sustained viral
suppression (!50 copies/ml) at longest follow-up (72–96 weeks). Successful MDT
obtained a great immune recovery: the median rise in absolute and percentage of
CD4C cells was 261 and 4 at week 24 and it reached 480 and 16 at 72–96 weeks.
Adverse events were common but generally manageable. Mild/moderate gastroin-
testinal complaints and laboratory abnormalities were detected in 5/11 and 8/11
MDT. Grade 2 severity pancreatitis occurred in one case with chronic active hepatitis
C. Pancreatitis resolved within 30 days of MDT interruption.
Conclusions. MDT may be a therapeutic option in children who failed to respond to
most standard HAART regimens.
Q 2004 The British Infection Society. Published by Elsevier Ltd. All rights reserved.Infection Society. Published by
2-39042265; fax:C39-02-
unimi.it (A. Vigano`).Introduction
Clinical trials and observational studies have shown
that highly active antiretroviral treatment (HAART)
has dramatically decreased AIDS related mortality
and morbidity in HIV-infected adults and children.1,2
However, rates of virologic failure, varying from 20
to 50%, have been reported within the first year ofJournal of Infection (2005) 50, 404–411
www.elsevierhealth.com/journals/jinfElsevier Ltd. All rights reserved.
Multi-drug therapy in pediatrics 405triple drug therapy in adult patients. Furthermore,
rates of virologic failure increase with each
successive round of therapy.3
In pediatric patients, the virologic response to
HAART and the long term control of viral replication
seem worse than adult ones. Thus, some studies
showed a virologic failure ranging from 20 to 30%,
while other studies showed that less than 50% of
children maintained a control of viral replication.4–7
These differences observed between children and
adults could be associated with one or many of the
following: higher baseline plasma HIV-1 RNA levels,
previous treatment with mono- or dual-therapy for
a long time allowing the presence of highly resistant
HIV strains, intolerance to one or more drugs and
insufficient drug absorption or poor patients
compliance.
Multiple drug therapy (MDT) has been used in
adult patients who have failed previous HAART
regimens and were not considered to be likely to
achieve a long lasting virologic response with
standard HAART regimens. In several studies MDT
showed an encouraging viral response rate, with 40–
50% patients reaching complete virologic suppres-
sion.8–13 In addition, a recent study showed that
MDT is associated with an improvement on clinical
outcome; thus, rates of survival in MDT recipients
were comparable with those in patients initiating
HAART.14 So far, this therapeutic strategy has been
assessed in a single pediatric study. King et al.
demonstrated that the use of five or more anti-
retroviral agents or four antiretrovirals plus hydro-
xyurea in 12 HIV-infected children achieved notable
virologic response with a tolerable safety profile.15
Here, we report the virologic, immunologic and
safety outcome of MDT in heavily antiretroviral pre-
treated HIV-infected children who failed more than
two protease inhibitor (PI)-based HAART regimens.Materials and methods
Patients and study design
We included in the study seven HIV-infected
children, followed at L. Sacco Hospital, Milan,
Italy, who had previously failed at least two
separate courses of PI-based HAART regimens.
These subjects received 11 courses of MDT regi-
mens consisting of four or more concurrent anti-
retroviral agents. These regimens were chosen
according to patients’ history of previous antire-
troviral exposure, tolerability and genotypic anti-
retroviral resistance testing results. The patient’s
primary physician (A.V.), with the expert advice ofthe study’s virologist (S.R.), determined the
specific MDT regimen. Antiretroviral drug doses
were calculated for each antiretroviral drug on
body weight or surface area and adjusted according
to patients’ growth.
The efficacy assessment of MDT regimen was
planned at 24 weeks. At that time, all patients with
virologic response were offered the opportunity to
continue the treatment, while patients with vir-
ologic failure could discontinue the treatment or
start a new MDT regimen according to the results of
a new genotypic resistance testing.
Children were included with informed parental
consent and the study protocol was approved by L.
Sacco Hospital Ethical Committee.Treatment outcome evaluation
Patients were followed monthly during MDT for
clinical outcome, immunologic and virologic
responses and development of adverse effects.
Quantitation of HIV-1 RNA was performed by the
Roche Amplicor HIV-1 Monitor test, Version 1.0
(Roche Diagnostic Systems, Branchburg, NJ)
according to the manufacturer’s specifications.
Virologic response was defined asR1 log10 decrease
in plasma RNA at 24 weeks.
T cells subset was determined from blood
samples collected in potassium-EDTA by standard
2-color fluorescent-activated cell sorter analysis
using the Coulter EPICS XL Flow Cytometry System
(Coulter Electronics, Miami, FL).
Laboratory monitoring for toxicity of antiretro-
virals included white blood cell count, platelets,
serum creatinine, transaminase, cholesterol, tri-
glycerides, total bilirubin and amylase. Toxicity was
defined as a change from laboratory baseline values
to a value greater than Grade 2 severity according
to the Paediatric Aids Clinical Trials Group toxicity
tables.16 Patients were questioned at each visit
about potential side effects including abdominal
pain, peripheral numbness and tingling; all were
informed to seek immediate attention if any signs
or symptoms occurred.Adherence
Before initiating MDT, the goal of complete viral
suppression was discussed with families and, when
appropriate, with children. The families were
provided with written instructions regarding
dosages and frequency of administration of pre-
scribed medications. Personal of the HIV team
frequently contacted families by telephone after
the regimen was started. Adherence to the regimen
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priate, with children at each follow-up visit;
difficulties with medications during the past months
were sorted out and attempts were made to remove
obstacles to compliance.Resistance testing
The RNA was extracted by kit QUIAamp HIV
(Quiagen, Inc., Chatsworth, CA), according to the
manufacturer’s recommendation, and converted
into cDNA using 10 000 HIV-1 copies.
The PRO gene was amplified using 10 ml of cDNA
and specific primers. Outer primers were P7 and
P8.17 The second amplification was performed with
10 ml of the first amplification product. The inner
primers for the protease region were PRO-F and
PRO-R.18
Unincorporated primers and nucleotides were
removed with QUIAquick spin columns (Quiagen)
and PCR products were directly sequenced using
internal primers and ABI sequencing kit reagents
with dye-labelled dideoxy terminators (Applied
Biosystems, Inc., Foster City, CA). A DNA automatic
sequencer (ABI PRISMe 377, Applied Biosystem,
Inc.) was utilized.
Sequences were edited by Facturae software
and aligned with the HIV-1 IIIB consensus sequence
by Sequence Navigatore software program (Applied
Biosystem).Results
Patient demographics
Demographic, clinical, and antiretroviral treatment
features of the seven patients included in the study
are shown in Table 1. Subjects (six males/one
female) ranged in age from 5.3 to 14.4 years and all
of them had a diagnosis of AIDS (CDC clinical
category C) and severe CD4C T cells depletion
(CDC immune category 3).
The median number of previous antiretrovirals
used was 8 (range: 5–13); the median number of
previous antiretroviral regimens was 6 (range: 3–9)
and the median time of prior exposure to anti-
retroviral therapy was 84 months (range: 62–114).
Among the patients, five were previously treated
with NRTI monotherapy, seven with double NRTI
therapy, and seven with a median number of 3
(range: 2–5) triple combination therapy. Overall,
the patients were previously exposed to a total of
22 HAART regimens, including: 15 combinations
with two NRTIsC1 PI, five combinations with oneNRTIC1 NNRTIC1 PI, one combination with two
NRTIsC1 NNRTI and one combination with one
NRTIC2 PIs. Thus, 100% of the patients had prior
exposure to NRTIs and PIs and 70% of patients had
prior exposure to NNRTIs.
MDT regimens included from 4 to 7 drugs. The
great majority of regimens (8/11) was composed
with one NNRTI and 1–3 NRTIs and PIs, while the
other regimens (3/11) were composed with 2–3
NRTIs and 2–4 PIs.
All patients received the MDT for 24 weeks at
least; the median duration of MDT was 72 weeks
(range: 24–96). Five children received one course of
MDT regimen and other two children received two
(patient 1) and four (patient 7) courses of MDT
regimens each. None of the patients had medi-
cations delivered by gastrostomy tube and one
patient (patient 7) required a naso-gastric tube for
the first two courses of MDT.
MDT was permanently discontinued in 2/11
courses: for virologic failure at week 24 in one
case and for voluntary cessation by the patient at 72
weeks in the other one.Analysis of genotypic resistance at baseline
Genotypic sequences were obtained at 11 time-
points from seven patients before the beginning of
any new MDT and in 10/11 cases without interrup-
tion of the current antiretroviral treatment.
Primary mutations were found in all cases against
the relevant PI that was administered in the last
failing regimen. Mutations in the protease gene,
related to PI resistance were found in all patients;
in particular, L10I was found in four samples, K20R
in four samples, D30N in one sample, I54V in 5
samples, and A71V in 6 samples. As far as UPAMs
(universal PI-associated mutations: changes at
codons 33, 82, 84, and 90), Fig. 1 indicates a
discrete presence of these peculiar mutations in a
variable percentage of children at baseline, with
the exception of the simultaneous presence of four
UPAMs in the same sample. All samples but two
presented at least three mutations, with three out
11 sequences showing more than eight codon
changes.
The sequence of the RT fragment of pol gene
(Fig. 1) showed the presence of M184V mutation in
5/11 samples. All children had a previous history of
ZDV treatment, and R3 NAMs (nucleoside-associ-
ated mutations) were seen in 81.8% of samples.
Some children were treated with d4T, but V75T was
never observed. NNRTI-related mutations appeared
at a lower frequency, with K103N and G190E seen in
three samples.
Table 1 Patients characteristics and summary of antiretroviral regimens
Patient Sex Age (yrs) BMI
(kg/m2)
CDC
stage
Prior ARV
exposure
Duration
of prior
ARV
exposure
(mos)
Prior ARV
regimens
MDT regimen Duration
of MDT
(weeks)
1 M 5.3 16.1 C3 AZT, 3TC,
ddI, IDV, RTV
62 5 d4T, NVP,
RTV, NFV
24
M 7.3 16.5 C3 3TC, ABC,
RTV, SQV,
APV, LPV/RTV
96
2 M 14.3 18.5 C3 AZT, d4T,
3TC, ddI,
NVP, IDV
79 6 ddI, ABC,
APV, IDV
96
3 M 13.6 19.1 C3 AZT, d4T,
3TC, ddI,
ddC, NVP,
IDV, NFV
84 6 d4T, ddI,
ABC, EFV,
APV
96
4 M 12.9 14.7 C3 AZT, d4T,
3TC, ABC,
EFV, IDV,
LPV/RTV
86 3 ddI, TDF, EFV,
SQV, APV,
RTV
24
5 M 14.4 14.1 C3 AZT, d4T,
3TC, ddI,
ddC, RTV,
NFV, LPV/RTV
89 6 TDF, EFV,
APV, LPV/RTV
96
6 F 11.2 16.0 C3 AZT, d4T,
3TC, ddI,
ddC, NVP,
IDV, RTV, NFV
114 7 ddI, EFV,
SQV, RTV,
LPV/RTV
72
7 M 7.0 12.4 C3 AZT, d4T,
3TC, ddI,
ddC, ABC,
NVP, EFV,
IDV, RTV,
NFV, SQV,
APV
81 9 d4T, ddI, 3TC,
NVP, SQV,
NFV, RTV
24
M 7.5 13.3 C3 ddI, d4T, 3TC,
NVP, RTV,
APV, IDV
24
M 8.0 17.4 C3 d4T, ddI, 3TC,
EFV, SQV,
RTV, LPV/RTV
72
M 10.0 15.2 C3 ddI, 3TC,
TDF, SQV,
LPV/RTV
96
Note. Yrs, years; BMI, body mass index; ARV, antiretroviral therapy; mos, months; MDT, multiple drug therapy; AZT, zidovudine;
d4T, stavudine; ddI, didanosine; 3TC, lamivudine; ABC, abacavir; ddC, zalcitabine; TDF, tenofovir; NVP, nevirapine; EFV, efavirenz;
NFV, nelfinavir; RTV, ritonavir; SQV, saquinavir; IDV, indinavir; APV, amprenavir; LPV, lopinavir.
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The median plasma HIV-1 RNA at baseline was
5:3 log10 copies/ml (range: 4.5–5.7 log10 copies/ml)
and HIV-1 RNAO5:0 log10 copies/ml was detectable
in nine cases. The median decrease in plasma HIV
RNA 24 weeks after initiation of MDT regimens was
2:0 log10 copies/ml (range: 0–3.87 log10 copies/ml).
Treatment success, defined as aR1 log10 decrease
in plasma HIV-1 RNA at week 24, was achieved in7/11 (64%) MDT courses. In these courses the
median HIV-1 RNA value obtained at this point
was 909 copies/ml, ranging from !50 to
4753 copies/ml. MDT who achieved a virologic
success kept a sustained viral suppression at longer
time point. Thus the HIV-1 RNA values available
at the longest follow-up (72–96 weeks) were
!50 copies/ml in all cases.
The median absolute and percentage of CD4C
cells count prior to the MDT regimens were 147 and
Figure 1 Baseline genotypic resistance profiles. NAMs, nucleoside-associated mutations; MNR, multi-nucleoside
resistance (changes at 151-associated codons in the reverse transcriptase region); PI, protease inhibitors; UPAMs,
universal PI-associated mutations (changes at codons 32, 82, 84 and 90 in the protease region).
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absolute and percentage of CD4C cells count of 261
(range: K44–433) and 4 (range: 1–15%) was
observed in successful MDT courses. At 72–96
weeks, CD4C cells showed a sustained increase
with a median rise in absolute and percentage of
480 (range: 459–1171) and 16 (range: 8–22%)
respectively.
Adherence
Adherence, as assessed through parental reports,
was greater than 95% (missing only one or two doses
a month) in 7/11 (64%) MDT courses. Adherence
difficulties have been reported in patient 4, in
patient 1 during his first MDT regimen and in patient
7 during his 2 first MDT regimens. All these MDT
regimens did not achieve treatment success at
week 24. Both patient 1 and 7 after instituting a
new MDT regimen achieved a virological
suppression.
Safety outcomes
Overall, gastrointestinal complaints occurred in
5/11 (45%) MDT courses. Four children complained
of mild to moderate gastrointestinal symptoms
including nausea, vomiting and abdominal pain.
Ondansetron was used for nausea prophylaxis in
three cases.
Laboratory abnormalities were detected in 5/7
(71%) children and these abnormalities occurred in
8/11 (73%) MDT courses. In the majority of cases,
biochemical and hematologic side effects were not
greater than Grade 2 severity according to the
Pediatric Aids Clinical Trials Group toxicity
tables.16 No children developed neutropenia orthrombocytopenia, while moderate anemia (hemo-
globin values ranging from 8.5 to 8.9 g/dl) were
detected in three children and overall during four
courses of MDT. Four children showed Grade 1
hypercholesterolemia with values ranging from 242
to 352 mg/dl. Four children showed Grade 1
hypertriglyceridemia with values ranging from 290
to 544 mg/dl, while one case developed Grade 3
hypertriglyceridemia after 72 weeks of MDT
(1920 mg/dl). This child was treated with gemfi-
brozil (1200 mg/day) for 24 weeks with a rapid
decrease of triglycerides levels (296 mg/dl after 3
months of therapy).
One child (patient 7), with chronic active
hepatitis C (moderate piecemeal necrosis, fibrous
expansion of portal areas with marked bridging and
moderate steatosis) showed increased serum levels
of alanine aminotransferase during three out of four
courses of MDT. This increase was mild with values
ranging from 124 to 167 UI/L. The same patient, at
72 weeks of the third MDT course, showed clinical
symptoms consistent with Grade 2 pancreatitis
(nausea, vomiting and abdominal pain) associated
with an elevation in pancreatic amylase of Grade 4
severity (2586 UI/L). The patient was receiving a
MDT regimen including stavudine and didanosine
and gancyclovir for secondary prophylaxis of CMV
infection. The symptoms and pancreatic amylase
normalized within 30 days of current MDT interrup-
tion and a new MDT was restarted.
Lastly, a case of autoimmune thyroiditis was
diagnosed in one child (patient 6). This patient had
a severe immunodepletion (CD4C count: 7 cells/ml)
before MDT and showed a wide immunerecovery
(CD4C count: 523 cells/ml) after 8 months from the
beginning of MDT. She presented with marked
asthenia and goitre and laboratory data showed
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increased TSH (44.2 mU/ml) and TG (55 ng/ml)
values, positive thyroid autoantibodies (Anti-TSM
123 UI/ml and anti-TG 666 UI/ml).
MDT was not discontinued and L-thyroxine
replacement therapy was initiated in this patient
with the resolution of symptoms during 6 months of
follow-up.Discussion
The management of patients who have failed
several previous courses of antiretroviral therapy
represents a major challenge in clinical practice.
Achievement and maintenance of viral load sup-
pression in patients who have not responded
virologically to a PI-containing regimen has proved
to be relatively uncommon, even more so among
triple class experienced patients.19,20 We studied a
group of heavily pre-treated children who had not
only failed to respond to more than 2 PI-containing
regimens, but also had an earlier AIDS diagnosis and
severe CD4C cells depletion. We adopted a multiple
drug rescue therapy regimen consisting of 4–7 drugs
on the base of patients’ history of previous
antiretroviral exposure, tolerability and genotypic
resistance testing.
We found a mean viral load decrease of 2:0 log10
after 24 weeks of MDT regimen. This change was
better than the one observed in an adult cohort
treated with 5–9 antiretrovirals ðK1:04 log10Þ and
similar to the results obtained ð2:0 log10Þ in children
treated with more than five antiretrovirals or four
antiretrovirals plus hydroxyurea.3–15 Treatment
success, defined as aR1 log10 decrease in plasma
HIV-1 RNA at week 24, was achieved in 64% of MDT
and this rate is comparable to what had been
reported (66%) in the previous pediatrics study.15
Moreover, the successful MDT regimens maintained
a sustained and prolonged control of viral replica-
tion: between weeks 72 and 96 of follow-up HIV-1
RNA was !50 copies/ml in all cases. These results
seem to be better than those obtained in the above
mentioned adult and pediatrics cohort (40%
between 47 and 57 weeks and 58% between 24 and
48 weeks, respectively).3,15
Due to the complexities of selecting effective
salvage treatment regimens and the high preva-
lence of drug-resistant virus in previously treated
patients, the use of drug-resistance assays to
evaluate a patient’s virus has a potential clinical
benefit for patient management. In addition,
recent data showed that therapy interruption notonly does not offer any advantage before salvage
regimen initiation, but it also could be unsafe.21–23
On the base of these observations, almost all
MDT regimens were started without interruption of
the current antiretroviral regimen. The results of
genotypic resistance tests allowed us to avoid the
administration of drugs that were indicated as
entirely compromised (e.g. the use of any single
PI) and to choose favorable combinations. The
great majority (10/11) of the regimens were
composed of a double PI-containing combination
including ritonavir. Virologic success in most
patients was probably related to the absence of
four UPAMs within the same genotype as well as the
favorable pharmacokinetic activity of ritonavir on
the regimens including others PIs.
The use of multiple drug regimens seems to
achieve a blunting immune reconstitution in HIV-
infected adults: some degree of CD4C cells count
increase has been observed in two studies, while
another one showed a lack of CD4C cells count
improvement.3,9,10 The thymic function recovery
during potent antiretroviral therapy may allow a
better immune reconstitution in pediatric
patients.24 Thus, an early and great CD4C cells
rise has been observed in naive as well as in NRTIs
experienced children following the initiation of
HAART.5,25,26 In addition, a recent study in NRTIs
and PIs experienced children showed that a 3–4 drug
regimen obtains at 48 weeks of treatment a mean
increase in CD4C cells count and percentage of 284
and 5.9, respectively.27 Our data show that suc-
cessful MDT regimens may obtain an impressive
immune recovery even in heavily antiretrovirals
pre-treated HIV-infected children with advanced
disease. Thus, we observed a median CD4C cell
increase of 261 and 480 cells at 24 and 72–96 weeks
of treatment, respectively.
Lack of adherence to the medication regimen has
been cited as the primary reason for failure of
HAART. Watson et al. found that only 58% of
children were adherent to their medications at
level of 75% or greater.28 We adopted a strong
support and monitoring of adherence through
frequent contacts with children and their families
and a careful assessment of parental and child
ability and commitment before initiation of MDT
regimens. In our study an adherence R95% was
achieved in 64% of MDT courses and it was
associated with virologic success. Therefore our
data suggest that this approach may be useful in
improving adherence in children. On the other
hand, non-adherence is confirmed to be the primary
cause of virologic failure.
Many healthcare workers and HIV-infected indi-
viduals are concerned that increased potency
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increased toxic effects. MDT in adult patients is
associated with a high frequency (86%) of either
laboratory abnormalities or subjective adverse drug
effects.3 In our study adverse drug effects were
relatively common and most of them were mild to
moderate. Subjective adverse drug effects, invol-
ving the gastrointestinal tract, were detected in
45% of MDT courses. Laboratory abnormalities
occurred in the 73% of MDT courses and alteration
in lipid profile was the most frequent abnormality.
Hyperamylasemia seems to be relatively fre-
quent (6%) in antiretroviral experienced children
treated with a 3–4 drugs regimen and pancreatitis
may occasionally occur.27 Moreover, an high fre-
quency of hyperamylasemia and pancreatitis has
been recently observed in HCV-coinfected
patients.29 We observed a case of Grade 2 severity
pancreatitis in one patient with chronic active
hepatitis C and who was receiving stavudine,
didanosine and gancyclovir. Clinical symptoms and
hyperamylasemia resolved within 30 days after the
interruption of the MDT courses and a new MDT
regimen was successfully restarted.
Lastly, an autoimmune thyroiditis was detected
in a child with severe immunodepletion who showed
a great recovery of CD4C cells and it did not
interfere with continuation of treatment. In the
HAART era a high rate of thyroid autoimmunity and
the occurrence of Graves’ disease have been
reported in deeply immunocompromised adult
patients after recovery of high number of CD4C
cells.30,31 Immune recovery disease may be
expected in patients with a favorable response to
MDT regimens and specially in children who have an
immune reconstitution capacity greater than
adults.
In summary, the HIV-infected children treatment
with MDT achieve a substantial antiviral response,
seems tolerable and it is associated with frequent,
but generally manageable, adverse event. These
results suggest that MDT deserves further consider-
ation for children who failed to respond to most
standard HAART regimens and it will allow to
selected patients to eventually benefit from more
attractive therapeutic options as they emerge.Acknowledgements
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